All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Addition of the first-in-class NEDD8-Activating Enzyme (NAE) inhibitor, pevonedistat (PEV), to azacitidine (AZA) was well tolerated in treatment-naïve Acute Myeloid Leukemia (AML) patients who are 60 years and over and unfit for intensive chemotherapy, according to results from a phase Ib study (NCT01814826) published in Blood on 18 January 2018, by Ronan T. Swords from the Sylvester Comprehensive Cancer Center, Miami, FL, and colleagues.
PEV works by disrupting cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumor cells via the deregulation of S-phase DNA synthesis. In preclinical studies, PEV enhances the anti-leukemic effects of AZA in AML cell lines. In this phase Ib dose-escalation study, Sword et al. aimed to investigate the safety and tolerability of PEV plus AZA in treatment-naïve older AML patients. The primary endpoints of the study were to determine the Dose Limiting Toxicity (DLT) and the Maximum Tolerated Dose (MTD) of PEV in combination with AZA.
In total, 64 AML patients with a median age of 75 years (range, 61 – 89 years) were enrolled in this study. Patients were administered intravenous (IV) PEV at either 20 mg/m2 (n = 6) or 30 mg/m2 (n = 3) on days 1, 3 and 5 plus a fixed dose of AZA (75 mg/m2 IV or subcutaneously) on days 1 – 5, 8 and 9, every 28 days until disease progression or unacceptable toxicity. Patients in the expansion cohort (n = 55) were treated at the MTD.
In summary, PEV in combination with AZA led to response rates and durable remissions with limited additional toxicity beyond what is expected for AZA alone. The authors concluded by noting that, the “timing and frequency of responses suggest potential benefit for the addition of PEV to standard regimen of single-agent AZA”.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox